'For
the quarter ending March 2024, consolidated net sales (including other operating income) of Natco Pharma has increased 18.98% to Rs 1068.3 crore compared to quarter ended March 2023. Profit before interest, tax and other unallocable items (PBIT) has jumped 47.91% to Rs 483.80 crore.
Overall PBIT margin rose from 36.43% to 45.29%.
Operating profit margin has jumped from 37.77% to 46.55%, leading to 46.65% rise in operating profit to Rs 497.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.48% to 11.77%. Purchase of finished goods cost fell from 6.13% to 2.87%. Employee cost decreased from 14.20% to 13.14%. Other expenses rose from 21.68% to 26.36%. Other income rose 44.83% to Rs 42 crore. PBIDT rose 46.51% to Rs 539.3 crore. Provision for interest rose 129.63% to Rs 6.2 crore. Loan funds ros...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
(31-Jan-2025)
Shree Cement
NP down 72.5% YoY to Rs 193.4 crore in Q3FY2025
-
(31-Jan-2025)
Star Cement
Revenue up 10.3% YoY to Rs 718.8 crore in Q3FY2025
-
|
|